Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031

globenewswire.com
BSX Boston Scientific Corporation is mentioned as a prominent company in the global interventional cardiology devices market, indicating its participation in a growing industry. MDT Medtronic is listed as a prominent player in the interventional cardiology devices market, suggesting its involvement in a sector with projected growth. ABT Abbott is identified as a prominent company within the interventional cardiology devices market, which is forecast to expand. EW Edwards Lifesciences Corporation is named as a prominent participant in the interventional cardiology devices market, which is expected to grow. TNDM Teleflex Incorporated is mentioned as a prominent company in the interventional cardiology devices market, which is projected to grow. PEN Penumbra, Inc. is listed as a prominent company in the interventional cardiology devices market, which is expected to experience growth. COO Cook is identified as a prominent company in the interventional cardiology devices market, indicating its participation in a growing sector. INTC Integer Holdings Corporation is mentioned as a prominent company in the global interventional cardiology devices market, which is projected to grow.

Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031 Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.

The global interventional cardiology devices market is projected to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, registering a CAGR of 6.4% during the forecast period. Rising cardiovascular disease incidence, an aging global population, and increasing demand for minimally invasive procedures are driving market expansion.

Technological advances in drug-eluting stents, bioresorbable scaffolds, catheter-based techniques, and enhanced imaging are improving procedural safety and clinical outcomes. Growth is also supported by expanding healthcare infrastructure in developing countries, favorable reimbursement policies in developed markets, and greater awareness of cardiovascular disease detection and treatment.

Plain angioplasty balloons forecast to record the highest segment CAGR

Based on angioplasty balloon type, the old or normal, also referred to as plain, angioplasty balloons segment is expected to register the highest CAGR. Demand is supported by comparatively low costs, broad clinical acceptance, and extensive use in routine and first-line percutaneous coronary interventions, particularly in developing and cost-sensitive healthcare markets.

Plain angioplasty balloons are widely used for lesion preparation before stent placement and in uncomplicated coronary and peripheral procedures. Their established safety record, ease of use, and availability across a wide range of sizes sustain adoption in high-volume hospitals, despite continuing advances in specialty balloon technologies.

Embolic protection devices expected to lead hemodynamic flow alteration device growth

Within the hemodynamic flow alteration devices category, embolic protection devices are projected to achieve the highest CAGR. Demand is increasing across cardiovascular and neurovascular interventions, including transcatheter aortic valve replacement, carotid artery stenting, and peripheral vascular procedures.

Growth is being reinforced by the need to reduce procedural strokes and distal ischemia, improve clinical outcomes, and expand treatment access. Product advances involving improved filters, greater capture efficiency, and easier deliverability are supporting adoption. Positive clinical evidence and rising use of minimally invasive procedures among older patients provide additional market momentum.

Guidewires positioned for strong growth across interventional procedures

The guidewires segment is expected to register the highest CAGR within the other devices category. Increasing volumes of percutaneous coronary angioplasty and other diagnostic and therapeutic interventions are creating sustained demand in hospitals and catheterization laboratories.

Guidewire innovation includes improved torque control, greater flexibility, hydrophilic coatings, and enhanced lesion-crossing capabilities. These developments have expanded use in complex interventions and chronic total occlusion procedures. Market growth is also supported by the global increase in cardiovascular disease, preference for minimally invasive treatment, and continued development of healthcare infrastructure in emerging economies.

Hospitals projected to remain the fastest-growing end-user segment

Hospitals are expected to record the highest CAGR among end users. A large share of angioplasties, stent placements, structural heart interventions, and other complex or high-risk procedures is performed in hospitals due to their advanced infrastructure, skilled interventional cardiologists, hybrid operating rooms, catheterization laboratories, and sophisticated imaging systems.

These facilities support the use of advanced technologies such as drug-eluting stents, rotational atherectomy, and intravascular ultrasound. Increasing adoption of minimally invasive techniques, favorable reimbursement for inpatient and outpatient cardiac interventions, and ongoing hospital investment in interventional technologies are expected to sustain segment growth.

Asia Pacific anticipated to post the highest regional CAGR

Asia Pacific is expected to achieve the highest CAGR in the interventional cardiology devices market during the forecast period. Regional expansion is associated with the increasing prevalence of cardiovascular diseases, rising numbers of catheter-based cardiac procedures, and investment in hospitals, catheterization laboratories, hybrid operating rooms, and advanced interventional technologies. Greater availability of skilled specialists and increasing adoption of minimally invasive cardiac procedures are also supporting market development.

Competitive landscape

Prominent companies operating in the global interventional cardiology devices market include Boston Scientific Corporation, Medtronic, Abbott, B. Braun SE, Terumo Corporation, Edwards Lifesciences Corporation, Koninklijke Philips N.V., Integer Holdings Corporation, Teleflex Incorporated, Penumbra, Inc., Cook, Cordis, iVascular S.L.U, Biosensors International Group, Ltd, BIOTRONIK SE & Co. KG, AMG International, ENDOCOR GmbH, InSitu Technologies, Inc., Meril Life Sciences, Alvimedica, Cardionovum GmbH, Medinol Ltd, Wellinq, Balton SP, and Translumina.

These market participants are based across the US, Germany, Japan, the Netherlands, Spain, Singapore, India, Istanbul, Turkey, and Poland, reflecting the increasingly global and competitive nature of interventional cardiology technology development.

Primary research participant profile

Report coverage and market analysis

The report estimates the size and growth potential of the interventional cardiology devices market across angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices, and end users. It includes a product portfolio matrix covering available interventional cardiology technologies, along with competitive analysis, company profiles, product offerings, and key market strategies.

The study evaluates major market drivers, including the growing prevalence of cardiovascular diseases, technological advances in interventional cardiology procedures, and the increased prevalence of diabetes. It also examines restraints such as the availability of alternative treatments and product recalls by industry participants that could limit equipment uptake.

Identified opportunities include rising coronary stent demand in developing countries and increasing product launches by leading companies in emerging markets. The analysis also addresses stringent regulatory requirements that can delay cardiac device approvals.

Additional coverage includes new product launches, anticipated technology trends, research and development activity, product and service enhancements, geographic expansion, recent industry developments, and investments. Emerging-market opportunities are assessed across all principal product and end-user segments.

The report is designed to help established market leaders and new entrants evaluate revenue opportunities within the overall interventional cardiology devices market and its subsegments. It provides insights into competitive positioning, go-to-market strategy development, market shares, growth plans, product and service portfolios, operational capabilities, and the principal drivers, restraints, challenges, and opportunities influencing the global market.

Key Attributes:

Key Topics Covered:

Market Dynamics Drivers

Challenges

Case Studies Industry Trends Opportunities

Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/1ko186

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.